Company Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease.
Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018.
The company was incorporated in 2017 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jan 31, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Jason Coloma |
Contact Details
Address: 171 Oyster Point Blvd, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650 850 5070 |
| Website | mazetx.com |
Stock Details
| Ticker Symbol | MAZE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001842295 |
| ISIN Number | US5787841007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jason Coloma, Ph.D. | Chief Executive Officer and Director |
| Harold S. Bernstein, M.D., Ph.D. | President, Research and Development and Chief Medical Officer |
| Courtney Phillips | General Counsel and Corporate Secretary |
| Atul Dandekar | Chief Strategy and Business Officer |
| Charles Homcy, M.D. | Chairman of the Board, Director |
| Nancy C. Andrews, M.D., Ph.D. | Director |
| Jamie Brush, M.D. | Director |
| Alan Colowick, M.D., M.P.H. | Director |
| Sekar Kathiresan, M.D. | Director |
| Jonathan Lim, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 10, 2025 | SCHEDULE 13G | Filing |
| Feb 7, 2025 | SCHEDULE 13G | Filing |
| Feb 7, 2025 | SCHEDULE 13G | Filing |
| Feb 7, 2025 | SCHEDULE 13G | Filing |
| Jan 31, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 31, 2025 | 424B4 | Prospectus |
| Jan 30, 2025 | EFFECT | Notice of Effectiveness |
| Jan 30, 2025 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Jan 30, 2025 | CERT | Certification by an exchange approving securities for listing |
| Jan 30, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |